Antibiotic therapy for osteoarticular infections in 2023: Proposals from the Pediatric Infectious Pathology Group (GPIP).


Journal

Infectious diseases now
ISSN: 2666-9919
Titre abrégé: Infect Dis Now
Pays: France
ID NLM: 101775152

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 14 09 2023
accepted: 18 09 2023
medline: 5 12 2023
pubmed: 24 9 2023
entrez: 23 9 2023
Statut: ppublish

Résumé

Most osteoarticular infections (OAI) occur via the hematogenous route, affect children under 5 years of age old, and include osteomyelitis, septic arthritis, osteoarthritis and spondylodiscitis. Early diagnosis and prompt treatment are needed to avoid complications. Children with suspected OAI should be hospitalized at the start of therapy. Surgical drainage is indicated in patients with septic arthritis or periosteal abscess. Staphylococcus aureus is implicated in OAI in children at all ages; Kingella kingae is a very common causative pathogen in children from 6 months to 4 years old. The French Pediatric Infectious Disease Group recommends empirical antibiotic therapy with appropriate coverage against methicillin-sensitive S. aureus (MSSA) with high doses (150 mg/kg/d) of intravenous cefazolin. In most children presenting uncomplicated OAI with favorable outcome (disappearance of fever and pain), short intravenous antibiotic therapy during 3 days can be followed by oral therapy. In the absence of bacteriological identification, oral relay is carried out with the amoxicillin/clavulanate combination (80 mg/kg/d of amoxicillin) or cefalexin (150 mg/kg/d). If the bacterial species is identified, antibiotic therapy will be adapted to antibiotic susceptibility. The minimum total duration of antibiotic therapy should be 14 days for septic arthritis, 3 weeks for osteomyelitis and 4-6 weeks for OAI of the pelvis, spondylodiscitis and more severe OAI, and those evolving slowly under treatment or with an underlying medical condition (neonate, infant under 3 months of old, immunocompromised patients). Treatment of spondylodiscitis and severe OAI requires systematic orthopedic advice.

Identifiants

pubmed: 37741341
pii: S2666-9919(23)00151-3
doi: 10.1016/j.idnow.2023.104789
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Amoxicillin 804826J2HU

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

104789

Informations de copyright

Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Mathie Lorrot (M)

General Pediatrics Department, Centre de Référence des Infections Ostéoarticulaires complexes (CRIOAc Pitié-Trousseau), France; Sorbonne Université, France; Pediatric Infectious Pathology Group of the French Pediatric Society, Créteil, France.

Yves Gillet (Y)

Pediatric Infectious Pathology Group of the French Pediatric Society, Créteil, France; Faculty of Medicine Lyon Est - Claude Bernard University Lyon 1, France; Pediatric Emergency and Intensive Care Service, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, France.

Romain Basmaci (R)

Pediatric Infectious Pathology Group of the French Pediatric Society, Créteil, France; Service de Pédiatrie-urgences, Hôpital Louis-Mourier, Colombes, France; Université Paris Cité et Université Sorbonne Paris Nord, Inserm, IAME, F-75018 Paris, France.

Camille Bréhin (C)

Pediatric Infectious Pathology Group of the French Pediatric Society, Créteil, France; Pédiatrie Générale, CHU Toulouse, France.

Marie-Aliette Dommergues (MA)

Pediatric Infectious Pathology Group of the French Pediatric Society, Créteil, France; Service de pédiatrie, Centre Hospitalier de Versailles, Le Chesnay, France.

Marion Favier (M)

Pediatric Infectious Pathology Group of the French Pediatric Society, Créteil, France; Service urgences post-urgences pédiatriques, CHU Bordeaux, Bordeaux, France.

Eric Jeziorski (E)

Pediatric Infectious Pathology Group of the French Pediatric Society, Créteil, France; Service urgences post-urgences pédiatriques, PCCEI, CeRéMAIA, Univ Montpellier, CHU Montpellier, Montpellier, France.

Luc Panetta (L)

Pediatric Infectious Pathology Group of the French Pediatric Society, Créteil, France; Faculty of Medicine Lyon Est - Claude Bernard University Lyon 1, France; Pediatric Emergency and Intensive Care Service, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, France.

Didier Pinquier (D)

Pediatric Infectious Pathology Group of the French Pediatric Society, Créteil, France; Department of Neonatal and Pediatric Intensive Care Medicine, Normadie University, UNIROUEN, INSERM U1245, CHU Rouen, 7600 Rouen, France.

Antoine Ouziel (A)

Pediatric Infectious Pathology Group of the French Pediatric Society, Créteil, France; Faculty of Medicine Lyon Est - Claude Bernard University Lyon 1, France; Pediatric Emergency and Intensive Care Service, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, France.

Emmanuel Grimprel (E)

General Pediatrics Department, Centre de Référence des Infections Ostéoarticulaires complexes (CRIOAc Pitié-Trousseau), France; Sorbonne Université, France; Pediatric Infectious Pathology Group of the French Pediatric Society, Créteil, France.

Robert Cohen (R)

Pediatric Infectious Pathology Group of the French Pediatric Society, Créteil, France; Université Paris Est, IMRB-GRC GEMINI, 94000 Créteil, France; Centre Hospitalier Intercommunal de Créteil, France; ACTIV, Association Clinique et Thérapeutique Infantile du Val de Marne, Créteil des Fossés, France. Electronic address: robert.cohen@activ-france.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH